Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-sequencing of human lymph node and peripheral blood T follicular helper cells

ABSTRACT: RNA-sequencing of human lymph node and peripheral blood T follicular helper cells

PROVIDER: PRJNA542639 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9047660.fastq.gz	Fastqsanger.gz
	SRR9047670.fastq.gz	Fastqsanger.gz
	SRR9047680.fastq.gz	Fastqsanger.gz
	SRR9047690.fastq.gz	Fastqsanger.gz
	SRR9047661.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 44

Similar Datasets

The BNT162b2 vaccine elicits robust lymph node T follicular helper cell responses

Project description:COVID-19 mRNA vaccines generate high concentrations of circulating anti-Spike antibodies and Spike-specific CD4+ T cells following prime-boost vaccination. It is not yet clear if vaccine-induced CD4+ T cell responses in the draining lymph node contribute to this outstanding immunogenicity. Using fine needle aspiration of draining axillary lymph nodes from individuals who received the BNT162b2 mRNA vaccine, we found large populations of Spike-specific CD4+ T follicular helper cells in the draining lymph node. A broadly immunodominant HLA-DPB1*04-restricted response to Spike166-180 composes one of the largest populations of T follicular helper cells in individuals with this allele, which is itself among the most common HLA alleles in the human population. Spike-specific T follicular helper cells are present in the lymph node 30 days after vaccine boost and persist in some individuals more than 170 days. Collectively, our results underscore the key role that robust T follicular helper cell responses play in the establishment of long-term immunity in this very efficacious human vaccine.

2022-01-04 | GSE183393 | GEO

The BNT162b2 vaccine elicits robust lymph node T follicular helper cell responses

Project description:The BNT162b2 vaccine elicits robust lymph node T follicular helper cell responses

| PRJNA760481 | ENA

RNA-sequencing of human lymph node and peripheral blood T follicular helper cells

Project description:Total mRNA-sequencing on memory T helper cell populations from human blood and lymph nodes.

2019-06-01 | GSE131089 | GEO

Follicular lymphoma lymph node

Project description:24 independent follicular lymphoma lymph node samples on LC microarrays was used to generate the gene lists in tables 2 and 3 of publication patients were divided into two groups, rituximab responders (composed of CR and PR) and non-responders (composed of NR and MR). Set of arrays organized by shared biological context, such as organism, tumors types, processes, etc. Keywords: Logical Set

2005-11-23 | GSE3647 | GEO

cDNA microarray assay of lymph node biopsies diagnosed as lymphoma or as reactive tissue

Project description:Gene expression profiling of biopsied human lymph node (LN) tissue comparing each patient sample against mobilised peripheral blood stem cells (PBSC), the reference channel Evaluate whether gene expression microarray can diagnose lymph node biopsies as reactive or as one of three main types of lymphoma: classical Hodgkin’s lymphoma (cHL), diffuse large B cell lymphoma (DLBCL) or follicular lymphoma (FL).

2012-11-28 | GSE23647 | GEO

cDNA microarray assay of lymph node biopsies diagnosed as lymphoma or as reactive tissue

2012-11-28 | E-GEOD-23647 | biostudies-arrayexpress

Human Thoracic Duct Lymph Contains Circulatory Intermediates T Follicular Helper Cells

Project description:Human Thoracic Duct Lymph Contains Circulatory Intermediates T Follicular Helper Cells

| PRJNA541437 | ENA

Microarray expression data from follicular lymphoma patients' lymph node biopsies (frozen)

Project description:Microarray expression data from follicular lymphoma patients' lymph node biopsies (frozen)

| PRJNA622992 | ENA

Immune and tumor cell gene expression from node positive and node negative breast cancers' primary tumor, lymph nodes and peripheral blood

Project description:Analysis of purified immune and breast tumor cells from three major compartments where cancer and immune cells interact: primary tumor, tumor draining lymph nodes (tumor invaded or tumor free), and peripheral blood. The results suggests that node-positive patients’ immune regulation and functionality is down-regulated compared to node-negative patients. CD45+ Immune and ESA+ tumor cells were purified from breast cancer patients' primary tumor, tumor-draining lymph node, and peripheral blood (ficoll) and placed onto Agilent microarrays using the dye-swap method. A universal human reference was used as a reference for the patient samples.

2013-01-11 | E-GEOD-41986 | biostudies-arrayexpress

Lymph node myeloid cells

Project description:Lymph node myeloid cells

| PRJNA895429 | ENA